UPDATED: Merck shares slide as response to its oral Covid antiviral plunges on latest update ahead of adcomm
After a second look, Merck says that its big breakthrough on the Covid front doesn’t look so good. An FDA adcomm of outside experts will take a look at the numbers on Tuesday and most likely recommend an EUA restricted to certain groups of people (i.e. not pregnant women or children).
The pharma giant updated its data on its oral antiviral molnupiravir on Friday, and said there’s a relative rate reduction of 30% for hospitalizations and deaths — a sharp plunge from the 50% relative rate reported at the beginning of October during their interim readout.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.